AI
Here are the biotech catalyst AI scanner results for the second week of November. This past week has been particularly challenging for many biotechs, especially in the rare disease sector, where numerous setbacks have negatively impacted market sentiment. General market volatility and a noticeable friction between the FDA and the
Rare Disease
Explore the volatile world of rare disease biotechs in 2025, from Novartis's $12B Avidity acquisition sparking optimism to FDA scrutiny causing stock plunges for uniQure and Sarepta.
Guide
Standard valuation metrics fail in biotech. Success requires different frameworks. I'll share my approaches—wins, losses, and lessons learned.
AI
I have significantly upgraded the catalyst scanner by integrating advanced machine learning algorithms that operate on static datasets and incorporating AI-driven features for greater analytical depth and quality. While these technological enhancements improve the scanner’s coverage and insight, it’s important to note that AI functions solely as
Inventiva
A 70% gain in two weeks should feel like victory. Instead, it exposed one of the most dangerous traps in biotech investing, and a lesson every ADR trader needs to know.
Solid Bioscience
Novartis's $12B acquisition of Avidity just repriced the gene therapy market, yet Solid Biosciences lags far behind. Top institutional investors see de-risked biology and standout safety in SLDB's early data. Are retail investors missing one of the most asymmetric opportunity in biotech?
Inventiva
First and only to hit both FDA surrogate endpoints in Phase 2b. Fully enrolled Phase 3, topline H2 2026. Most advanced oral MASH program outside approved Rezdiffra. Yet trading at $650M—1/6th~1/15th of comparable competitors.
SPRO
Spero Therapeutics sits at a $133 million market cap. GSK ranks its sole asset as a top-14 priority with $2.7 billion peak sales potential. Someone's wrong—and it's probably not the pharmaceutical giant holding 16% of the shares.
ALGS
For forty years, Hepatitis B has been medicine's greatest escape artist—suppressed but never caught. Now a battle-tested team thinks they've finally closed the trapdoor, and the market is betting they're wrong.
Aligos Therapeutics
Capsid modulators have failed before. The graveyard is full of promising molecules that couldn't escape resistance or deliver antigen reductions. So what makes Aligos think they've solved it?
Aligos Therapeutics
The HBV cure race isn't winner-takes-all. It's a puzzle where multiple pieces need to fit together. Aligos positioned itself at the center of every solution - but the validation picture is murkier than it first appears.
Aligos Therapeutics
When the market prices your company below its cash balance, two things are true: either you're about to zero, or someone made a terrible mistake. At Aligos, the next 18 months will determine which.